Search

Author/Creator Shen, Meiying

1. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer. (30th August 2022)

Authors:
Xu, Yingkun; Shen, Meiying; Peng, Yang; Liu, Li; Tang, Lingfeng; Yang, Ting; Pu, Dongyao; Tan, Wenhao; Zhang, Wenjie; Liu, Shengchun
Other Names:
Xu Yuzhen Academic Editor.
Journal:
BioMed research international
Issue:
Volume 2022(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients. (20th April 2022)

Authors:
Xu, Yingkun; Peng, Yang; Shen, Meiying; Liu, Li; Lei, Jinwei; Gao, Shun; Wang, Yuan; Lan, Ailin; Li, Han; Liu, Shengchun
Other Names:
Raza Faisal Academic Editor.
Journal:
Journal of oncology
Issue:
Volume 2022(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer. (2nd June 2022)

Authors:
Xu, Yingkun; Shu, Dan; Shen, Meiying; Wu, Qiulin; Peng, Yang; Liu, Li; Tang, Zhenrong; Gao, Shun; Wang, Yuan; Liu, Shengchun
Other Names:
Cui Dawei Academic Editor.
Journal:
Journal of immunology research
Issue:
Volume 2022(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗